Harvard Bioscience

Harvard Bioscience Current Liabilities

The Current Liabilities of Harvard Bioscience (HBIO) as of Sep 21, 2026 is 17.14 M USD. In the previous year, Current Liabilities was 96.28 M USD — a change of -82.20% (lower).

Current Liabilities

17.14 MUSD

YoY

-82.20%

Last updated:

Current Liabilities of Harvard Bioscience is 2026 17.14 M USD. Current Liabilities of Harvard Bioscience was 2025 96.28 M USD. It decreases by -82.20% lower compared to the previous year.

The Harvard Bioscience Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
28.08 M USD
Jan 1, 2019
30.05 M USD
Jan 1, 2020
26.30 M USD
Jan 1, 2021
35.23 M USD
Jan 1, 2022
32.28 M USD
Jan 1, 2023
37.27 M USD
Jan 1, 2024
96.28 M USD
Jan 1, 2025
17.14 M USD
The Harvard Bioscience Current Liabilities history
YEARCurrent LiabilitiesYoY
17.14 MUSD-82.20%
96.28 MUSD+158.31%
37.27 MUSD+15.47%
32.28 MUSD-8.37%
35.23 MUSD+33.96%
26.30 MUSD-12.50%
30.05 MUSD+7.01%
28.08 MUSD+38.66%
20.25 MUSD-2.99%
20.88 MUSD-15.41%
24.68 MUSD-6.48%
26.39 MUSD+3.71%
25.45 MUSD+96.97%
12.92 MUSD+4.39%
12.38 MUSD-17.31%
14.97 MUSD-1.24%
15.16 MUSD+6.73%
14.20 MUSD-24.90%
18.91 MUSD-11.85%
21.45 MUSD+41.37%
15.17 MUSD-9.78%
16.82 MUSD-101.40%
-1.20 BUSD+6.33%
-1.13 BUSD-20.99%
-1.43 BUSD-14,869.62%
9.67 MUSD+8.57%
8.90 MUSD+1,384.08%
600,000.00USD
Access this data via the Eulerpool API

Harvard Bioscience Stock analysis

What does Harvard Bioscience do? Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world. Harvard Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harvard Bioscience stock

Current Liabilities of Harvard Bioscience is 17.14 M USD in 2026.

Current Liabilities of Harvard Bioscience changed from 96.28 M USD to 17.14 M USD, representing a -82.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Harvard Bioscience since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Harvard Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Harvard Bioscience

All Key Metrics — Harvard Bioscience